Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research

Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research


National Glaucoma Research
Current Award

Zhenhua Xu

Zhenhua Xu, Ph.D.

Johns Hopkins University
Baltimore, MD

Title: Role of Nrf2 in Protecting RGC in Glaucoma
Non-Technical Title: Protective Role of Nrf2 in Glaucoma

Elia J. Duh, M.D.
Johns Hopkins University

Duration: July 1, 2013 - June 30, 2015
Award Type: Standard
Award Amount: $100,000


Oxidative stress and inflammatory processes are thought to play important roles in the development and progression of glaucoma. The research proposed in this application will determine the role of NF-E2-related factor 2 (Nrf2, a critical cellular stress-responsive protein) in preventing ganglion cell death. Dr. Xu and colleagues will also evaluate the potential of Nrf2 activation drugs in preventing cell death and vision loss in a mouse model of glaucoma.


The proposed research will determine the potential of targeting NF-E2-related factor 2 (Nrf2) for the treatment of vision loss in glaucoma.

Vision loss in glaucoma results from progressive retinal ganglion cell (RGC) death. Oxidative stress and inflammatory processes play important roles in the development and progression of glaucoma. Nrf2 is considered to control one of the most important cellular pathways to protect against oxidative stress, and it also has an important role as a negative regulator of inflammation, essentially dialing-down the out-of-control inflammation associated with many diseases. Dr. Xu and colleagues will use cell culture studies and a mouse model of glaucoma to determine whether regulating Nrf2 will help promote RGC survival. The first aim of the study is to determine whether the activation or inactivation of Nrf2 affects RGC survival when exposed to oxidative stress. The second aim of the study is to test the potential of using a drug to activate Nrf2 toprotect RGCs in a mouse model of glaucoma. The proposed research could help to develop a new treatment strategy for glaucoma. In addition, this work will further the understanding of the role of oxidative stress and inflammation in the development and progression of glaucoma.

Investigator Biography:

Dr. Xu is a Research Associate at the Wilmer Eye Institute in the Johns Hopkins University School of Medicine in Baltimore, MD. She completed her doctoral studies at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, China. Her research is focused on determining the neuroprotective role of Nrf2 in retinal ganglion cells (RGCs) and the potential of Nrf2 pharmacologic activation for the treatment of glaucoma.